{"data":{"ModuleTitle":{"label":"Module Title","value":"Company Description"},"CompanyName":{"label":"Company Name","value":"INmune Bio Inc."},"Symbol":{"label":"Symbol","value":"INMB"},"Address":{"label":"Address","value":"225 NE MIZNER BOULEVARD,SUITE 640, BOCA RATON, Florida, 33432, United States"},"Phone":{"label":"Phone","value":"+1 858 964-3720"},"Industry":{"label":"Industry","value":"Biotechnology: Biological Products (No Diagnostic Substances)"},"Sector":{"label":"Sector","value":"Health Care"},"Region":{"label":"Region","value":"North America"},"CompanyDescription":{"label":"Company Description","value":"INmune Bio Inc is a clinical-stage biotechnology company. It is engaged in the development of new immunotherapies that reprogram a patient's innate immune system to allow the immune system to fight cancer. The company's pipeline products includeINKmune, INBO3, XPro1595, LIVNate, and others."},"CompanyUrl":{"label":"Company Url","value":"https://www.inmunebio.com"},"KeyExecutives":{"label":"Key Executives","value":[{"name":"Mark Lowdell","title":"Chief Scientific & Manufacturing Officer"},{"name":"Raymond J. Tesi","title":"Chairman, President, Chief Executive Officer & CMO"},{"name":"Tara Lehner","title":"Vice President-Clinical Operations"}]}},"message":null,"status":{"rCode":200,"bCodeMessage":null,"developerMessage":null}}